BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ezurpimtrostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ezurpimtrostat\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05874414-10941@assetmemo.bio
DTSTAMP:20261121T005422Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ezurpimtrostat: Phase 1/2 readout est. (NCT05874414)
DESCRIPTION:Ezurpimtrostat\, phase 1/2\, Cholangiocarcinoma with KRAS Mutat
 ion.\nStudy: Combination of GNS561 and Trametinib in Patients With Advance
 d KRAS Mutated Cholangiocarcinoma\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ezurpimtrostat#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0587
 4414
URL:https://assetmemo.bio/drug/ezurpimtrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
